KJHP
MTNB icon

K.J. Harrison & Partners’s Matinas BioPharma MTNB Stock Holding History

K.J. Harrison & Partners’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,269
Closed -$150K – 170
2018
Q3 		$150K Buy
+3,269
New +$70.3K 0.04% 185

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

K.J. Harrison & Partners's MTNB Position: Q4 2018 in Review

K.J. Harrison & Partners sold out of Matinas BioPharma (MTNB) in Q4 2018, closing a stake of 3,269 shares — an estimated $150K sold.

K.J. Harrison & Partners first reported a position in MTNB in Q3 2018 and held it in 1 quarter. The position peaked at $150K in Q3 2018. 35 funds tracked by Wall St. Rank hold MTNB as of Q4 2018.

  • K.J. Harrison & Partners reported no remaining Matinas BioPharma position as of Q4 2018 after selling out during the quarter.
  • K.J. Harrison & Partners sold 3,269 Matinas BioPharma shares in Q4 2018, an estimated $150K.
  • K.J. Harrison & Partners first reported a position in Matinas BioPharma in Q3 2018 and held it in 1 quarter.
  • K.J. Harrison & Partners's Matinas BioPharma position peaked at $150K in Q3 2018.
  • 35 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2018.

Based on K.J. Harrison & Partners's 13F filing for Q4 2018, filed 24 Jan 2019.